B1+rms for Implants: A Review of Intended Use
Listen to this summary
The authors aim to clarify the advantages of the B1+rms metric over the Specific Absorption Rate (SAR) for assessing radiofrequency exposure in Active Implantable Medical Devices (AIMDs) during MRI procedures. They highlight that while SAR is traditionally used for patient safety, B1+rms offers a more precise evaluation of AIMD/RF interactions, thereby improving the safety and effectiveness of MR Conditional labeling. The review addresses common confusions regarding B1+rms computation and application, ultimately advocating for its adoption in clinical settings.
This is one of 33,000+ journals available on OSLR. Try it free for 14 days.
Free 14-day trial. 33,000+ journals. Cancel anytime.
More from Journal of magnetic resonance imaging : JMRI
View all →Jun 11, 2026 · Journal of magnetic resonance imaging : JMRI
Effects of Acute Aerobic Exercise and Task Repetition on the Neural Correlates of Executive Function in Young and Older Adults: A Crossover fMRI Study
Jun 11, 2026 · Journal of magnetic resonance imaging : JMRI
MR Imaging-Based Biomarkers for Strength Prediction: A Statistical Shape and Architecture Modeling of Quadriceps Muscles
More in Internal Medicine
View all →Jun 25, 2026 · Blood
Combining Quizartinib with intensive chemotherapy in older patients with newly diagnosed AML: results of the UK NCRI AML18 Trial
Jun 25, 2026 · Blood
Translational Regulation of Sf1 Integrates Alternative Splicing and Hematopoietic Stem Cell Fate
Jun 25, 2026 · Blood
Galectin-1 Fuels Monocyte Hyperinflammation and Represents a Novel Therapeutic Target in Myeloproliferative Neoplasms
Jun 25, 2026 · The American journal of sports medicine
Association of Central Acetabular Osteophytes With Microinstability and Increased Combined Anteversion in Borderline Dysplasia Hips
Jun 25, 2026 · Blood
NG2-ITGA4 axis regulates Rho GTPases and leukemic aggressiveness in KMT2A-r B-ALL and is targetable with natalizumab
Jun 24, 2026 · Lancet (London, England)
Safety, pharmacokinetics, and exploratory efficacy of the oral ghrelin receptor agonist AC01 in heart failure with reduced ejection fraction (GOAL-HF1): a randomised, double-blind, placebo-controlled, phase 1b/2a study
"Oslr has become part of my weekly routine on my day off. The clinical relevance of the summaries is outstanding — I'd rate it 9/10. Being able to consume research hands-free is a huge advantage for busy physicians."
Dr. Jennifer Thompson
Portland, OR
Stay current without falling behind
33,000+ journals. 3-minute audio summaries. Free for 14 days.
